{"id":2326,"date":"2021-03-11T15:02:25","date_gmt":"2021-03-11T13:02:25","guid":{"rendered":"http:\/\/www.internalmed-journal.in.ua\/?p=2326"},"modified":"2021-11-16T15:12:25","modified_gmt":"2021-11-16T13:12:25","slug":"%d0%ba%d0%b0%d1%80%d0%b2%d0%b5%d0%b4%d1%96%d0%bb%d0%be%d0%bb-%d0%bf%d1%80%d0%be%d1%82%d0%b8-%d0%bc%d0%b5%d1%82%d0%be%d0%bf%d1%80%d0%be%d0%bb%d0%be%d0%bb%d1%83-%d1%81%d1%83%d0%ba%d1%86%d0%b8%d0%bd","status":"publish","type":"post","link":"http:\/\/www.internalmed-journal.in.ua\/en\/archives\/2326","title":{"rendered":"Carvedilol versus metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction"},"content":{"rendered":"

Prof. E.Ya. Nikolenko, PHD K.V. Vovk, ass. professor E.L. Pavlova, ass. professor O.A. Salun V.N. <\/strong><\/p>\n

V.N. Karazin Kharkiv National University<\/strong><\/p>\n

Department of General Practice-Family Medicine, Faculty of Medicine <\/strong><\/p>\n

Choosing the best drug for the treatment of cardiac patients remains one of the most important aspects of medical practice. The purpose of this review is to select the optimal beta-blocker for the treatment of patients with chronic heart failure and patients with acute myocardial infarction by comparing the efficacy of carvedilol and metoprolol succinate, as both drugs significantly reduce mortality rates and reduce hospitalization. The results of meta-analyzes, randomized trials comparing the efficacy of carvedilol and metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction were analyzed. Conflicting data received. According to the study \u201cEffect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction\u201d, a meta-analysis published in the American Journal of Cardiology in 2013, carvedilol is significantly more effective than metoprolol succinate in treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction, while meta-analyzes of 2015 and 2017 showed no preference for carvedilol over metoprolol succinate. Based on the results, concluded that the data obtained is not sufficient to argue that carvedilol is more effective than metoprolol succinate for this category of patients in terms of reducing the risk of all-cause mortality, cardiovascular mortality, and reducing hospitalization. This problem requires further extensive research.<\/p>\n

Key words<\/strong>: beta-blocker, heart failure, acute myocardial infarction, carvedilol, metoprolol succinate.<\/p>\n

\u00a0<\/strong>https<\/strong>:\/\/<\/strong>dx<\/strong>.<\/strong>doi<\/strong>.<\/strong>org<\/strong>\/10.15407\/internalmed2021.01.036<\/strong><\/a><\/p>\n

Download<\/strong>.<\/strong>PDF (ukr)<\/strong><\/a><\/p>\n

For citing:<\/strong><\/p>\n

1. \u041d\u0456\u043a\u043e\u043b\u0435\u043d\u043a\u043e, \u0404.\u042f., \u0412\u043e\u0432\u043a, \u041a.\u0412., \u041f\u0430\u0432\u043b\u043e\u0432\u0430, \u041e.\u041b., \u0421\u0430\u043b\u0443\u043d, \u041e.\u041e. \u041a\u0430\u0440\u0432\u0435\u0434\u0456\u043b\u043e\u043b \u043f\u0440\u043e\u0442\u0438 \u043c\u0435\u0442\u043e\u043f\u0440\u043e\u043b\u043e\u043b\u0443 \u0441\u0443\u043a\u0446\u0438\u043d\u0430\u0442\u0443 \u043f\u0440\u0438 \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u0456 \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0456\u0437 \u0441\u0435\u0440\u0446\u0435\u0432\u043e\u044e \u043d\u0435\u0434\u043e\u0441\u0442\u0430\u0442\u043d\u0456\u0441\u0442\u044e \u0437\u0456 \u0437\u043d\u0438\u0436\u0435\u043d\u043e\u044e \u0444\u0440\u0430\u043a\u0446\u0456\u0454\u044e \u0432\u0438\u043a\u0438\u0434\u0443 \u043b\u0456\u0432\u043e\u0433\u043e \u0448\u043b\u0443\u043d\u043e\u0447\u043a\u0430 \u0442\u0430 \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0456\u0437 \u0433\u043e\u0441\u0442\u0440\u0438\u043c \u0456\u043d\u0444\u0430\u0440\u043a\u0442\u043e\u043c \u043c\u0456\u043e\u043a\u0430\u0440\u0434\u0430 \/\/ \u0421\u0445\u0456\u0434\u043d\u043e\u0454\u0432\u0440\u043e\u043f\u0435\u0439\u0441\u044c\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b \u0432\u043d\u0443\u0442\u0440\u0456\u0448\u043d\u044c\u043e\u0457 \u0442\u0430 \u0441\u0456\u043c\u0435\u0439\u043d\u043e\u0457 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0438. – 2021. – \u21161. \u2013 \u0421. 36-39. doi: 10.15407\/internalmed2021.01.036<\/p>\n

2. Nikolenko EYa, Vovk KV, Pavlova OL, Salun OO. [Carvedilol versus metoprolol succinate in the treatment of patients with heart failure with reduced ejection fraction and patients with acute myocardial infarction]. Shidnoevr. z. vnutr. simejnoi med. 2021;1:36-39. Ukrainian. doi: 10.15407\/internalmed2021.01.036<\/p>\n

References:<\/strong><\/p>\n

\u00a01. 2013 ACCF\/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; doi: 10.1016\/j.jacc.2013.05.019.
\nhttps:\/\/doi.org\/10.1016\/j.jacc.2013.05.019<\/p>\n

2. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi.org\/10.1093\/ eurheartj\/ehw128.<\/p>\n

3. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure – Web Addenda. European Heart Journal. doi:10.1093\/eur- heartj\/ehw128.<\/p>\n

4. 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/ AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology. American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136: e137-e16
\nhttps:\/\/doi.org\/10.1161\/CIR.0000000000000509<\/p>\n

5. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure. J Am Coll Cardiol. 2019;74 (15):1966-2011.
\nhttps:\/\/doi.org\/10.1016\/j.jacc.2019.08.001<\/p>\n

6. Abolbashari M, Macaulay T, Whayne T, Mukherjee D, Saha S. Polypharmacy in Cardiovascular Medicine: Problems and Promises!. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2017;15(1):. http:\/\/dx.doi.org\/10.2174\/1871525715666170529093442
\nhttps:\/\/doi.org\/10.2174\/1871525715666170529093442<\/p>\n

7. Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346(jan16 1):f55-f55. http:\/\/dx.doi.org\/10.1136\/bmj.f55
\nhttps:\/\/doi.org\/10.1136\/bmj.f55<\/p>\n

8. Chatterjee S, Udell J, Sardar P, Lichstein E, Ryan J. Comparable Benefit of \u03b2-Blocker Therapy in Heart Failure Across Regions of the World: Meta-analysis of Randomized Clinical Trials. Canadian Journal of Cardiology. 2014;30(8):898-903. http:\/\/dx.doi.org\/10.1016\/j.cjca.2014.03.012
\nhttps:\/\/doi.org\/10.1016\/j.cjca.2014.03.012<\/p>\n

9. Hulkower S, Aiken \u0412, Stigleman S. Clinical inquiry: what is the best beta-blocker for systolic heart failure? J. Fam. Pract. 2015;64 (2):122-123.<\/p>\n

10. Rogers C, Bush N. Heart Failure: pathophysiology, diagnosis, medical treatment guidelines, and nursing management. Nurs. Clin. North Am. 2015;50(4):787-799.
\nhttps:\/\/doi.org\/10.1016\/j.cnur.2015.07.012<\/p>\n

11. Riabenko DV. Beta-blokator\u044b pry serdechnoi nedostatochnosty: prystaln\u044bi vzghliad na karvedylol. Medychna hazeta \u00abZdorovia Ukrainy\u00bb. 4 (65): 29-31. Ukrainian<\/p>\n

12. Rekomendatsii Asotsiatsii kardiolohiv Ukrainy z diahnostyky ta likuvannia khronichnoi sertsevoi nedostatnosti (2017). Asotsiatsiia kardiolohiv Ukrainy, Ukrainska asotsiatsiia fakhivtsiv iz sertsevoi nedostatnosti. Ukrainian<\/p>\n

13. Rekomendatsii shchodo vedennia patsiientiv iz sertsevoiu nedostatnistiu zi znyzhennoiu fraktsiieiu vykydu livoho shlunochka. Medychna hazeta \u00abZdorovia Ukrainy\u00bb. 2019; 6 (67): 44-48. Ukrainian<\/p>\n

14. Khronichna sertseva nedostatnist u doroslykh: diahnostyka ta likuvannia. Medychna hazeta \u00abZdorovia Ukrainy\u00bb.2019;6 (67): 42-43. Ukrainian<\/p>\n

15. Hasanov YuCh, Rudyk YuS, Lozik TV. Otsinka vplyvu metoprololu suktsynatu na parametry yakosti zhyttia, klinichnyi status, pokaznyky hemodynamiky ta rytmu sertsia u patsiientiv z khronichnoiu sertsevoiu nedostatnistiu na tli ozhyrinnia. Ukrainskyi terapevtychnyi zhurnal. 2016;1:61- 67. Ukrainian<\/p>\n

16. Ajam T, Ajam S, Devaraj S, Mohammed K, Sawada S, Kamalesh M. Effect of carvedilol vs metoprolol succinate on mortality in heart failure with reduced ejection fraction. American Heart Journal. 2018;199:1-6. http:\/\/dx.doi.org\/10.1016\/j.ahj.2018.01.005
\nhttps:\/\/doi.org\/10.1016\/j.ahj.2018.01.005<\/p>\n

17. Briasoulis A, Palla M, Afonso L. Meta-Analysis of the Effects of Carvedilol Versus Metoprolol on All-Cause Mortality and Hospitalizations in Patients With Heart Failure. The American Journal of Cardiology. 2015;115(8):1111-1115. http:\/\/dx.doi.org\/10.1016\/j.amjcard.2015.01.545
\nhttps:\/\/doi.org\/10.1016\/j.amjcard.2015.01.545<\/p>\n

18. DiNicolantonio J, Lavie C, Fares H, Menezes A, O’Keefe J. Meta-Analysis of Carvedilol Versus Beta 1 Selective Beta-Blockers (Atenolol, Bisoprolol, Metoprolol, and Nebivolol). The American Journal of Cardiology. 2013;111(5):765-769. http:\/\/dx.doi.org\/10.1016\/j.amjcard.2012.11.031
\nhttps:\/\/doi.org\/10.1016\/j.amjcard.2012.11.031<\/p>\n

19. Chung J, Han J, Kim Y, Kim C, Ahn Y, Chan Cho M, Chae S, Chae I, Chae J, Seong I, Yang H, Park K, Kang H, Koo B, Jeong M, Kim H, Ahn T, Cha K, Gwon H, Hwang J, Joo S, Kim D, Kim K, Oh D, Oh S, Seung K, Yoon J. Benefit of Vasodilating \u03b2\u2010Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study. Journal of the American Heart Association. 2017;6(10):. http:\/\/dx.doi.org\/10.1161\/jaha.117.007063
\nhttps:\/\/doi.org\/10.1161\/JAHA.117.007063<\/p>\n

20. Seo G, Kim D, Kim K, Song P. Impact of carvedilol versus \u03b21-selective \u03b2- blockers (bisoprolol, metoprolol, and nebivolol) in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am Heart. 2015;116(10):1502-1508.
\nhttps:\/\/doi.org\/10.1016\/j.amjcard.2015.08.013<\/p>\n

21. Li J, Chen Z, Gao X, Zhang H, Xiong W, Ju J, Xu H. Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction. The American Journal of Cardiology. 2017;120(9):1479-1486. http:\/\/dx.doi.org\/10.1016\/j.amjcard.2017.07.036
\nhttps:\/\/doi.org\/10.1016\/j.amjcard.2017.07.036<\/p>\n","protected":false},"excerpt":{"rendered":"

Prof. E.Ya. Nikolenko, PHD K.V. Vovk, ass. professor E.L. Pavlova, ass. professor O.A. Salun V.N. V.N. Karazin Kharkiv National University Department of General Practice-Family Medicine, Faculty of Medicine Choosing the best drug for the treatment of cardiac patients remains one of the most important aspects of medical practice. The purpose of this review is to…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9,15,54],"tags":[],"translation":{"provider":"WPGlobus","version":"2.12.2","language":"en","enabled_languages":["uk","en","ru"],"languages":{"uk":{"title":true,"content":true,"excerpt":false},"en":{"title":true,"content":true,"excerpt":false},"ru":{"title":true,"content":true,"excerpt":false}}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/2326"}],"collection":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/comments?post=2326"}],"version-history":[{"count":7,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/2326\/revisions"}],"predecessor-version":[{"id":2954,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/posts\/2326\/revisions\/2954"}],"wp:attachment":[{"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/media?parent=2326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/categories?post=2326"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.internalmed-journal.in.ua\/en\/wp-json\/wp\/v2\/tags?post=2326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}